4) Moss RA, Bothos J, Pate1 P, et a1. Complete resultsfrom phase 1 dose-escalation study of MetMAb, amonovalent antagonist antibody to the receptorMet, dosed as single agent and in combination with bevacizumab in patients with advanced solid ma-lignancies[abstract #4378] . 36th ESMO Congress ;2011 Sept 23-27 ; Stockholm, Sweden.